# Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Source: https://onco.cc/trials/nct03967977/  
OnCo record `nct03967977` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tislelizumab, Cisplatin, Gemcitabine and Carboplatin in bladder & urothelial cancer, run by BeiGene, active and no longer recruiting.

## Summary

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma is a phase 3 interventional study registered as NCT03967977 by BeiGene, with 420 participants enrolled, started 2019-05-29 and due to reach its primary completion in 2027-06-30. Interventions recorded: Tislelizumab, Placebo, Cisplatin, Gemcitabine Hydrochloride and Carboplatin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03967977
- Phase: 3
- Setting: A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Either Cisplatin or Carboplatin +Gemcitabine + Tislelizumab Compared With Either Cisplatin or Carboplatin + Gemcitabine + Placebo as First-line Treatment for Patients With Locally Advanced or Metastatic Urothelial Carcinoma
- Sponsor: BeiGene
- Enrolled: 420

## Sources

- ClinicalTrials.gov NCT03967977: https://clinicaltrials.gov/study/NCT03967977

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct03967977.json